Conquering Prediabetes: Battle of Metformin Versus Lifestyle Makeover
DOI:
https://doi.org/10.36283/PJMD13-3/003Keywords:
Pre Diabetes, FBS, HbA1C, Lifestyle Modification, MetforminAbstract
Background: Prediabetes is a metabolic condition characterized by blood sugar levels higher than normal but below the diabetic range. The onset of microvascular complications may set in this phase, hence intervening during the prediabetic stage becomes crucial in halting the progression to irreversible diabetes. We compared blood sugar levels between lifestyle modification and metformin medication and identified which option is better for managing prediabetes.
Methods: A quasi-experimental study was done from January to October 2023 recruiting 150 prediabetic adults coming to Sikander Abad clinic through convenience sampling including 18 to 65 years of age while obese adults, those who had hypoglycemia within the past 3 months, and GDM women were excluded. Patients were divided into two groups and given a choice to choose pharmacotherapy (Metformin) or non-pharmacological measures (lifestyle modification). A thorough history and examination were done on all patients and Fasting Blood Sugar was done initially and after 3 months. SPSS version 21 was used. Independent and paired sample T-tests were used and chi-square was computed to see associations with the demographic factors. P-value <0.05 was considered significant.
Results: Prediabetes was better controlled with Metformin (FBS-3.2mg/dl) as compared to lifestyle modification (FBS-2.7mg/dl) in our study (p<0.02). Non-obese patients constituted a higher proportion of the cohort, with 91(60%) compared to 59(39.3%) obese patients. Additionally, 43.3% of the study participants aimed to delay or prevent the onset and complications of Diabetes Mellitus.
Conclusion: In our study, starting Metformin in the prediabetes phase, prevents or delays the progression to full-blown diabetes, contributing to a 0.5mg/dl reduction in glycemic control.
Keywords: Prediabetes, Hb A1c, Glycemic Control, Metformin.
References
Shahid MB, Saeed M, Naeem H, Kumari U. Diabetes mellitus: Is Pakistan the epicenter of the next pandemic? Chronic Dis Transl Med. 2023 Sep 28;10(1):75-77. doi: 10.1002/cdt3.96.
Edwards CM, Cusi K. Prediabetes: A Worldwide Epidemic. Endocrinol Metab Clin North Am. 2016;45(4):751-764. doi: 10.1016/j.ecl.2016.06.007.
Khan RMM, Chua ZJY, Tan JC, Yang Y, Liao Z, Zhao Y. From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research. Medicina (Kaunas). 2019;55(9):546. doi: 10.3390/medicina55090546.
American Diabetes Association. Standards of Medical Care in Diabetes-2017 Abridged for Primary Care Providers. Clin Diabetes. 2017;35(1):5-26. doi: 10.2337/cd16-0067.
Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-1350. doi: 10.1056/NEJM200105033441801.
Defronzo RA, Tripathy D, Schwenke DC, et al. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes. 2013;62(11):3920-3926. DOI: 10.2337/db13-0265.
Moin T, Li J, Duru OK, Ettner S, Turk N, Keckhafer A, Ho S, Mangione CM. Metformin prescription for insured adults with prediabetes from 2010 to 2012: a retrospective cohort study. Ann Intern Med. 2015;162(8):542-548. doi: 10.7326/M14-1773.
Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med. 2008;121(2):149-157.e2. doi: 10.1016/j.amjmed.2007.09.016.
Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C. Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013 Oct 15;159(8):543-551. doi 10.7326/0003-4819-159-8-201310150-00007.
Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577-1585. doi: 10.1007/s00125-017-4342-z.
Mousavi SS, Namayandeh SM, Fallahzadeh H, Rahmanian M, Mollahosseini M. Comparing the effectiveness of metformin with lifestyle modification for the primary prevention of type II diabetes: a systematic review and meta-analysis. BMC Endocr Disord. 2023;23(1):198. doi: 10.1186/s12902-023-01445-9.
Viskochil R, Malin SK, Blankenship JM, Braun B. Exercise training and metformin, but not exercise training alone, decreases insulin production and increases insulin clearance in adults with prediabetes. J Appl Physiol (1985). 2017;123(1):243-248. doi: 10.1152/japplphysiol.00790.2016.
Saito T, Watanabe M, Nishida J, Izumi T, Omura M, Takagi T, Fukunaga R, Bandai Y, Tajima N, Nakamura Y, Ito M; Zensharen Study for Prevention of Lifestyle Diseases Group. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch Intern Med. 2011;171(15):1352-60. doi: 10.1001/archinternmed.2011.275.
Skoglund G, Nilsson BB, Olsen CF, Bergland A, Hilde G. Facilitators and barriers for lifestyle change in people with prediabetes: a meta-synthesis of qualitative studies. BMC Public Health. 2022;22(1):553. doi: 10.1186/s12889-022-12885-8.
Aroda VR, Christophi CA, Edelstein SL, Zhang P, Herman WH, Barrett-Connor E, Delahanty LM, Montez MG, Ackermann RT, Zhuo X, Knowler WC, Ratner RE; Diabetes Prevention Program Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. J Clin Endocrinol Metab. 2015;100(4):1646-1653. doi: 10.1210/jc.2014-3761.
Galaviz KI, Narayan KMV, Lobelo F, Weber MB. Lifestyle and the Prevention of Type 2 Diabetes: A Status Report. Am J Lifestyle Med. 2015;12(1):4-20. doi: 10.1177/1559827615619159.
Moin T, Martin JM, Mangione CM, Grotts J, Turk N, Norris KC, Tseng CH, Jeffers KS, Castellon-Lopez Y, Frosch DL, Duru OK. Choice of Intensive Lifestyle Change and/or Metformin after Shared Decision Making for Diabetes Prevention: Results from the Prediabetes Informed Decisions and Education (PRIDE) Study. Med Decis Making. 2021;41(5):607-613. doi: 10.1177/0272989X211001279.
Haw JS, Galaviz KI, Straus AN, Kowalski AJ, Magee MJ, Weber MB, Wei J, Narayan KMV, Ali MK. Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2017;177(12):1808-1817. doi: 10.1001/jamainternmed.2017.6040.
Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S; Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142(8):611-619. doi: 10.7326/0003-4819-142-8-200504190-00009.
Sheng Z, Cao JY, Pang YC, Xu HC, Chen JW, Yuan JH, Wang R, Zhang CS, Wang LX, Dong J. Effects of Lifestyle Modification and Anti-diabetic Medicine on Prediabetes Progress: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2019;10:455. doi: 10.3389/fendo.2019.00455.
Lily M, Godwin M. Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician. 2009 Apr;55(4):363-369.
Hostalek U, Gwilt M, Hildemann S. Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs. 2015;75(10):1071-1094. doi:10.1007/s40265-015-0416-8.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
How to Cite
